Fisher Scientific International Inc
Fisher Scientific International — Merger or Acquisition (March 2004)
20 slides from Fisher Scientific International's merger presentation, Mar 17, 2004
Slide 1: Fisher Scientific International Inc.
Fisher Scientific International Inc. March 17, 2004
Slide 2: Safe Harbor Statement
This presentation contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on Fisher's and Apogent's current expectations and beliefs and are subject to a number of risks, uncertainties and a
Slide 3: Key Strategies: Apogent - A perfect fit
Key Strategies Increase proprietary product and service offering to enhance margins Capitalize on high growth life science footprint to accelerate revenue growth Pursue promising acquisition candidates Increase earnings and cash flow Apogent - A perfect fit
Slide 4: Apogent: A Product Leader
Apogent: A Product Leader Leading global manufacturer serving life science, scientific research and clinical markets Broad portfolio of consumable proprietary products Significant global presence Extensive technical selling capabilities
Slide 5: Improved Product Mix
Improved Product Mix Life Science Products 0.33 Scientific Research Products 0.18 Other Lab Equipment 0.17 Clinical Lab Products 0.32 Based on pro forma 2004 sales Life Science Products 0.18 Scientific Research Products 0.55 Lab Workstations 0.09 Clinical Lab Products 0.23 Pro forma 2004 sales $5 bi
Slide 6: Apogent Transaction Rationale
Apogent Transaction Rationale Enhances portfolio of propriety products and services Increases Fisher's life science footprint to $1.1 billion Strengthens Fisher's healthcare business Provides significant cost savings opportunities Increases cash flow generation
Slide 7: Creates a $1.1 Billion Life Science Footprint
Creates a $1.1 Billion Life Science Footprint Complementary life science product portfolio Enhanced microbiology offering Significant kitting opportunities Enhanced specialist selling organization 2002PF 2003PF 2004PF East 250 500 1100 Life Science Revenue ($ in millions)
Slide 8: Strengthens Fisher's Healthcare Business
Strengthens Fisher's Healthcare Business Expands proprietary product offering to clinical lab Leverages diagnostic manufacturing capabilities Increases specialist selling organization Enhances value for clinical lab customers
Slide 9: Increases Portfolio of Proprietary Products
2000 2004PF Distributed Products 0.6 Self-Manufactured 0.4 Increases Portfolio of Proprietary Products Enhances margins Distributed Products 0.4 Self-Manufactured 0.6
Slide 10: Transaction Terms
Transaction Terms
Slide 11: The New Fisher Scientific
The New Fisher Scientific Purchase Consideration: 0.56 FSH shares for each share of AOT (tax free) Pro Forma Ownership: Fisher: 57% Apogent: 43% Board Composition: Fisher: 6 Directors Apogent: 4 Directors, including Frank Jellinek, Chairman Emeritus Management: Chairman and CEO Paul Montrone Vice-Ch
Slide 12: Provides up to $100 Million of Synergies
Provides up to $100 Million of Synergies Operations Rationalize Fisher's and Apogent's manufacturing operations (e.g. diagnostics, microbiology, lab equipment) Enhance the efficiency of our sales and marketing efforts Leverage Fisher's disciplined approach to cash flow generation Capitalize on cross
Slide 13: Sales Growth
Sales Growth ($ in Billions) 2000 2001 2002 2003 2004F* 2005F* *Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Excludes the impact of foreign exchange. CAGR: 16%
Slide 14: Operating Margin Expansion
2000 2001 2002 2003 2004F* 2005F* East 0.068 0.073 0.075 0.078 0.106 0.134 Operating income as a percentage of sales - excludes goodwill amortization, restructuring and nonrecurring expenses. * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Operat
Slide 15: Earnings Per Share Growth
Earnings Per Share Growth ($ in Millions) 2000 2001 2002 2003 2004F* 2005F* Excludes goodwill amortization, restructuring and nonrecurring expenses. * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Excludes the effect of conversion of contingent c
Slide 16: Strong Operating Cash Flow
Strong Operating Cash Flow 2000 2001 2002 2003F 2004F 2005F ($ in millions) Free cash flow is cash from operations less capital expenditures. * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Memo: Free Cash Flow $78 $119 $115 $138 $215 $395 * *
Slide 17: Summary of Guidance
Summary of Guidance Note: Excludes goodwill amortization, restructuring and nonrecurring expenses and related charges. $ in millions, except EPS
Slide 18: Transaction Benefits
Transaction Benefits Enhances portfolio of proprietary products and services Increases Fisher's life science footprint to $1.1 billion Strengthens Fisher's healthcare business Provides significant cost savings opportunities Increases cash flow generation Strong management team
Slide 19: Fisher Scientific International Inc.
Fisher Scientific International Inc.
Slide 20: Additional information about the proposed merger
In connection with the proposed merger, Fisher Scientific and Apogent Technologies will file relevant materials with the SEC, including one or more registration statement(s) that contain a prospectus and a joint proxy statement. Investors and security holders are urged to read these documents (if an
Fisher Scientific International — Merger or Acquisition (March 2004) on 6ix